IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice.
about
Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumorsCAR models: next-generation CAR modifications for enhanced T-cell functionChimeric antigen receptor T-cell therapy for solid tumorsMesothelin-Targeted CARs: Driving T Cells to Solid TumorsTherapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapyInterleukin-7 and interleukin-15 for cancerConcise review: humanized models of tumor immunology in the 21st century: convergence of cancer research and tissue engineeringProliferation-linked apoptosis of adoptively transferred T cells after IL-15 administration in macaquesImproving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationCAR therapy: the CD19 paradigmPD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responsesIn vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomesThe basic principles of chimeric antigen receptor design.Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy.Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition.Modulation of mTOR Signalling Triggers the Formation of Stem Cell-like Memory T CellsDendritic cells enhance the activity of human MUC1-stimulated mononuclear cells against breast cancer.Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes.The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent.Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.Signal transducer and activator of transcription 3 (STAT3) mutations underlying autosomal dominant hyper-IgE syndrome impair human CD8(+) T-cell memory formation and function.Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer.Chimeric antigen receptor-redirected T cells return to the benchA cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model.Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptorChimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunityTethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cellsMultiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo.Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.Ex vivo gene transfer for improved adoptive immunotherapy of cancer.Chimeric antigen receptor modified T cell therapy for B cell malignancies.CAR T-cell immunotherapy: The path from the by-road to the freeway?Chimeric antigen receptors: driving immunology towards synthetic biology.The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells.Therapeutic T cell engineering.Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer.IL-21 promotes CD4 T cell responses by phosphatidylinositol 3-kinase-dependent upregulation of CD86 on B cells
P2860
Q26741260-3A51917D-9F6B-4538-B38B-D7C39397652BQ26745600-0B897C01-09EF-47A0-8F86-07D6D55E5DF1Q26750908-35EDD302-8829-4E37-9C42-942077DC7124Q26778759-B05DADA4-292C-46C6-AD6C-880FEACDBD23Q26779938-04F3492C-DDAA-4C8B-B1B8-23B22D9D5D64Q26830709-94909D6C-7D27-4B37-8747-368BC8DC8063Q27022477-88EA03EC-41E8-4B5A-AA06-E2E7421E5E82Q27314843-DC9B90DF-CFDC-45ED-BBAC-03FF22D84321Q28068378-4A78D8D5-D81B-4AE7-8017-5F3257E8292AQ28081642-3ACC12A3-1187-4F60-9A00-A28A2CD5B87BQ30600094-10D72979-DB1D-4661-A05B-642FCD679BE6Q33716478-B191E0CF-FC62-4002-80FF-72CA9E62F722Q34036213-53C9DC47-D447-4A64-B006-F795B3767E11Q34122292-7757436D-BCC4-4FC5-872C-46B07798AFBCQ34363238-D4913660-8820-4100-8C69-82ACF62DB7FDQ34987908-F13DEFA3-39BA-4EBF-806A-43213C1A37F6Q35223241-0A106B1A-0D64-47FF-933F-0B2EBC3D879DQ35673845-9CA8B6BE-A44E-4CD2-838E-C36793D6F44DQ36645067-68DCBAE9-67F1-4AB1-938B-6073F9D165D7Q36694948-7DECBFDB-0C52-49A4-AE19-FE27CB59BB0DQ36801106-B19EE854-B102-46ED-8AE5-5E20694F8B94Q36863278-F39615CA-46E1-421A-AD0F-D08456903001Q37137924-E945A15B-9295-4F06-B254-652ECD81C212Q37202661-EC502FBF-BC19-4AD3-80E8-F51A87B43476Q37233539-8D1F7926-DFBD-44F0-8959-D4ABACF2E5D8Q37301510-DC5FC069-47DE-4E62-8385-3E0CDCDCB71AQ37362636-ADE23AE2-B276-4341-AD52-FBA1AA5620DFQ37434176-677D5EF7-DD29-41C9-8BE9-C34E8443A6C3Q37469199-90CF857E-0C26-4C03-8404-5DB8EC557DD7Q37474007-49776D5B-E6D0-42ED-AA02-B04323B8886BQ37696129-E76EEEE0-70DD-41DA-B9E3-2CAADCCE8A2CQ37706835-AA67D3BB-0959-45ED-9909-07E4A2B13946Q37854259-EBF8E04B-29D3-46F3-9ADD-3CE6ABC7D74BQ38171402-3B11DF51-B5F9-4AA6-9650-0E2924CF2482Q38632105-93860FDB-716E-4C61-9D65-3C5C6E5A79FEQ38884383-C357050D-3CD4-43D1-B7C2-2B4B9B418814Q40095245-DF3B193F-8C85-4DDC-B78E-634527DB2AE9Q40199809-251A6C19-EB2E-4B36-B80C-E9D771A41528Q41925180-BE481793-DD81-412E-90D2-ACA926A699A2Q41973852-0FCB698C-B2F4-4BA6-8886-38283FB25974
P2860
IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
IL-7 and IL-21 are superior to ...... phoma in immunodeficient mice.
@ast
IL-7 and IL-21 are superior to ...... phoma in immunodeficient mice.
@en
type
label
IL-7 and IL-21 are superior to ...... phoma in immunodeficient mice.
@ast
IL-7 and IL-21 are superior to ...... phoma in immunodeficient mice.
@en
prefLabel
IL-7 and IL-21 are superior to ...... phoma in immunodeficient mice.
@ast
IL-7 and IL-21 are superior to ...... phoma in immunodeficient mice.
@en
P2860
P1433
P1476
IL-7 and IL-21 are superior to ...... phoma in immunodeficient mice.
@en
P2093
John C Markley
Michel Sadelain
P2860
P304
P356
10.1182/BLOOD-2009-09-241398
P407
P577
2010-02-26T00:00:00Z